Drug Trial Radar · NCT05133180
Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)
Last checked: Nov 20, 2026Latest source record: Jun 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
Jan 19, 2022
Primary completion
Sep 22, 2022
Study completion Dec 19, 2022
Sponsor
- Lead sponsor
- Dompé Farmaceutici S.p.AIndustry
- Sponsor type
- Industry
- First posted
- Nov 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary objectives * To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) \>10mm/5min at Week 4 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in Symptom Assessment in Dry Eye questionnaire (SANDE) global score at Week 12 by testing the superiority. Secondary objectives * To compare the efficacy of cenegermin vs vehicle in Schirmer I test at Week 4, 8, 12 and 16 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in Cornea and conjunctiva vital staining with fluorescein (National Eye Institute \[NEI\] scales) at Week 4, 8, 12 and 16 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in Tear Film Break-Up Time (TFBUT) at Week 4, 8, 12 and 16 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in SANDE scores at Week 8, 12 and 16 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in worsening in symptom scores (SANDE) and/or NEI score at Week 4 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in impact of dry eye on everyday life (IDEEL) questionnaire at Week 4, 8, 12 and 16 by testing the superiority.
Conditions
- Dry Eye
Interventions
OxervateDrug
Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID).
VehicleOther
Vehicle will be instilled with the same scheme of the test product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients Reaching a Value of Schirmer I Test (Without Anaesthesia) >10mm/5min at Week 4Time frame: at week 4
- Change From Baseline in Symptoms Questionnaire (SANDE) Global Score at Week 12Time frame: at week 12
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Lugene Eye Institute - Glendale Office
Glendale, California
David Wirta, M.D. & Associates
Newport Beach, California
The Johns Hopkins University
Baltimore, Maryland
Tufts University School of Medicine (TUSM) - New England Eye Center/Tufts Medical Center - Boston
Boston, Massachusetts
Houston Eye Associates HEA - Gramercy Location
Houston, Tennessee
Toyos Clinic - Nashville
Nashville, Tennessee
Virginia Eye Consultants (VEC) - Norfolk Office
Norfolk, Virginia
AOU Gaspare Rodolico - Ospedale San Marco
Catania, Italy
Università degli Studi di Milano - Ospedale San Giuseppe - UO Oculistica
Milan, Italy
AOU Policlinico Umberto I - Dipartimento Organi di Senso - Clinica Oculistica
Roma, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.